- AU$57.85m
- AU$54.97m
- AU$2.67m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 24.95 | ||
| Price to Tang. Book | 24.95 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 19.11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -352.17% | ||
| Return on Equity | -457.46% | ||
| Operating Margin | -269.86% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.3 | 0.23 | 0.99 | 1.96 | 2.67 | n/a | n/a | 65.46% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
PainChek Ltd is an Australia-based company, which develops pain assessment technologies. The Company's principal activities are development and commercialization of mobile medical device applications that provide pain assessment for individuals that are unable to communicate with their carers. The Company's PainChek Universal is a complete point-of-care solution that combines the existing PainChek Application with the numerical rating scale (NRS). PainChek Application uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalize pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the NRS, a standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 27th, 2010
- Public Since
- May 1st, 2012
- Sector
- Software & IT Services
- Industry
- Technology
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 1,807,762,509
- Address
- Suite 401, 35 Lime Street, SYDNEY, 2000
- Web
- https://www.painchek.com/
- Phone
- +61 893888290
- Auditors
- BDO Audit Pty Ltd
Upcoming Events for PCK
Similar to PCK
3P Learning
Australian Stock Exchange - SEATS
5G Networks
Australian Stock Exchange - SEATS
8Common
Australian Stock Exchange - SEATS
ActivePort
Australian Stock Exchange - SEATS
Adisyn
Australian Stock Exchange - SEATS
FAQ
What is the PainChek share price?
As of Today at 22:32 UTC, shares in PainChek are trading at AU$0.03. This share price information is delayed by 15 minutes.
How has the PainChek share price performed this year?
Shares in PainChek last closed at AU$0.03 and the price had moved by +10.52% over the past 365 days. In terms of relative price strength the PainChek share price has outperformed the ASX All Ordinaries Index by +8.87% over the past year.
What are the analyst and broker recommendations for PainChek?
The overall consensus recommendation for PainChek is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the PainChek dividend yield?
PainChek does not currently pay a dividend.
Does PainChek pay a dividend?
PainChek does not currently pay a dividend.
When does PainChek next pay dividends?
PainChek does not currently pay a dividend.
How do I buy PainChek shares?
To buy shares in PainChek you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of PainChek?
As of the previous close price of AU$0.03, shares in PainChek had a market capitalisation of AU$57.85m.
Where are PainChek shares listed?
Here are the trading details for PainChek:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PCK
What kind of share is PainChek?
Based on an overall assessment of its quality, value and momentum PainChek is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a PainChek share price forecast for 2025?
The analyst consensus target price for shares in PainChek is AU$0.08. That is 150% above the last closing price of AU$0.03.
Analysts covering PainChek currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the PainChek share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like PainChek. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +7.66%.
As of the last closing price of AU$0.03, shares in PainChek were trading +4.24% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the PainChek PE Ratio?
The PainChek PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of PainChek?
PainChek's management team is headed by:
- Scott Robertson - CTO
- Sally McDow - SEC
- Adam Davey - NED